Institute for Protein Design, University of Washington

New Capabilities

As of September 2026: Designed 21h10

Pancreatic cancer ignores nearly every approved immunotherapy, and the new KRAS inhibitors shrink tumors only until resistance emerges. A study published online this week in Cell pairs those inhibitors with a designer mimic of the immune signal IL-21 — and in mice, the combination cleared pancreatic tumors and kept them clear for months.

Updated Sep 24